AstraZeneca’s Evusheld Covid-prevention drug gets UK approval

Treatment aimed at people who cannot be vaccinated is boost to firm's coronavirus portfolio

AstraZeneca has received UK regulatory approval for its long-acting Covid-19 antibody treatment Evusheld in a boost to its coronavirus portfolio, as the British-Swedish drugmaker targets greater drug development success at its new 1bn research lab in Cambridge.

Aimed at preventing Covid infections in people with poor immune systems who cannot be vaccinated, Evusheld is already approved in the US, France and other countries, and the US government has ordered 1.7m doses.